Guillaume Barriere
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Guillaume Barriere has a total of 121 co-authors. Here are the top co-authors by number of shared publications:
François Durand
Affiliation Medical Affairs, Gilead Sciences S.A.S., Boulogne-Billancourt, France
4 shared publications- Anne-Geneviève Marcelin
Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, AP-HP, Hôpitaux Universitaires Pitié-Salpêtrière-Charles Foix, Laboratoire de Virologie, 75013 Paris, France
3 shared publications - Clotilde Allavena
Infectious Disease Department, Nantes University Hospital, Inserm 1413, Nantes, France
2 shared publications - Fabrice Bonnet
CHU de Bordeaux and Bordeaux University, BPH, INSERM U1219, 33076 Bordeaux, France
2 shared publications - Jade Ghosn
Université de Paris Cité, Paris, France
2 shared publications - Laurent Hocqueloux
Infectious Disease Department, Orléans University Hospital, Orléans, France
2 shared publications
Latest Publications
- Open Access
- 19 August 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
Lenacapavir use in France: a national, observational study (LENAddOn)
Context: The LENAddOn study aimed to: characterize PWH initiating injectable lenacapavir (LEN) post-early access program in France; assess LEN continuation rates at W26 and W52; describe reasons for LEN discontinuation. Methods: Observational, retrospective study across 19 centers, including people with HIV-1 who initiated LEN between 20/06/2023 and 30/06/2024. Socio-demographic, clinical, and laboratory data were extracted from medical records. The primary outcome was the proportion of PWH receiving a second and third set of LEN injections at W26 and W52. Results: 77 PWH were included (median age 57 years [IQR 44-63]; duration of ART 25 years [17-29]), with a history of frequent adherence issues and vulnerability factors. At LEN initiation, 22 (28.6%) had a plasma HIV-1 viral load (pVL) ≥200 copies/mL and 43 (55.8%) a pVL <50 copies/mL; 42 (54.6%) had viral resistance to ≥2 drugs in ≥3 classes. 21 participants (27.3%) received injectable ART associating LEN plus cabotegravir ± rilpivirine. LEN continuation rate was 94.8% (95% CI 87.2-98.6) at W26, and 81.8% (71.4-89.7) at W52, with 4 LEN discontinuations between D0 and W26, and 10 between W26 and W52. Main reasons for LEN discontinuation were: death unrelated to LEN/lost-to-follow-up (n=5), persistence of viral replication (n=3) and injection site reactions (ISRs, n=2). Last measured pVL during the study period was <200 cp/mL in 72/77 participants (93.5%), and <50 cp/mL in 61/77 (79.2%). Conclusion: LEN use allowed simplification of antiretroviral regimens, with the maintenance or achievement of virological suppression. Continuation of LEN at W26 and W52 remained high among a population with extensive treatment history.
- 19 August 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
Open AccessLenacapavir use in France: a national, observational study (LENAddOn)
Context: The LENAddOn study aimed to: characterize PWH initiating injectable lenacapavir (LEN) post-early access program in France; assess LEN continuation rates at W26 and W52; describe reasons for LEN discontinuation. Methods: Observational, retrospective study across 19 centers, including people with HIV-1 who initiated LEN between 20/06/2023 and 30/06/2024. Socio-demographic, clinical, and laboratory data were extracted from medical records. The primary outcome was the proportion of PWH receiving a second and third set of LEN injections at W26 and W52. Results: 77 PWH were included (median age 57 years [IQR 44-63]; duration of ART 25 years [17-29]), with a history of frequent adherence issues and vulnerability factors. At LEN initiation, 22 (28.6%) had a plasma HIV-1 viral load (pVL) ≥200 copies/mL and 43 (55.8%) a pVL <50 copies/mL; 42 (54.6%) had viral resistance to ≥2 drugs in ≥3 classes. 21 participants (27.3%) received injectable ART associating LEN plus cabotegravir ± rilpivirine. LEN continuation rate was 94.8% (95% CI 87.2-98.6) at W26, and 81.8% (71.4-89.7) at W52, with 4 LEN discontinuations between D0 and W26, and 10 between W26 and W52. Main reasons for LEN discontinuation were: death unrelated to LEN/lost-to-follow-up (n=5), persistence of viral replication (n=3) and injection site reactions (ISRs, n=2). Last measured pVL during the study period was <200 cp/mL in 72/77 participants (93.5%), and <50 cp/mL in 61/77 (79.2%). Conclusion: LEN use allowed simplification of antiretroviral regimens, with the maintenance or achievement of virological suppression. Continuation of LEN at W26 and W52 remained high among a population with extensive treatment history.
- Open Access
- 7 March 2026
- Published by Wiley in HIV Medicine
- Vol. 27 (6) , 965-978
Real‐world use of second‐generation integrase strand transfer inhibitors ( INSTI ) as switch therapy in the prospective ANRS ‐ CO3 ‐ AquiVIH ‐ NA cohort
Objectives: To characterize real‐world treatment switching in France to bictegravir (BIC or B) or dolutegravir (DTG)‐based regimens with a focus on treatment persistence, effectiveness (HIV‐1 RNA ≤50 copies/ml) and particular attention to the prevalence and incidence of comorbidities. Methods: People living with HIV from the prospective ANRS‐CO3‐AquiVIH‐NA cohort, who switched from effective antiretroviral treatment (ART) to a BIC‐ or DTG‐based regimen between 2018 and 2021, were eligible for analysis. Results: A total of 2275 people living with HIV were included (52% receiving B/F/TAF, 8% DTG/3TC/ABC, 18% DTG/RPV, 22% DTG/3TC) with a median age of 53–56 years and a comorbidity prevalence of 71%–75% across treatment groups (chronic kidney disease (CKD) 15%–25%, diabetes mellitus 15%–19%, hypertension 57%–64%). Viral suppression rates at month 18 (LOCF, last observation carried forward) using a missing‐equals‐excluded (M = E) approach were 97% on B/F/TAF, 95% on DTG/3TC/ABC, 97% on DTG/RPV and 96% on DTG/3TC. Discontinuation rates were 16.5% for B/F/TAF, 37.5% for DTG/3TC/ABC, 16.7% for DTG/RPV and 17.3% for DTG/3TC, driven by adverse events in 5.6%, 12.5%, 5.6% and 6.1%, respectively. Comorbidity incidence rates/1000 person years in those free of the respective disease were 39 for hypertension, 22 for diabetes mellitus, 13 for cardiovascular events and 5 for CKD. Conclusions: In this real‐world cohort, treatment persistence 18 months after therapy switch was similar for B/F/TAF, DTG/RPV and DTG/3TC, but significantly lower for DTG/3TC/ABC. All regimens maintained high levels of viral suppression. Furthermore, the cohort illustrates the disease burden experienced by middle‐aged and elderly people living with HIV and highlights the importance of adapting ART to the specific needs of this population.
- 7 March 2026
- Published by Wiley in HIV Medicine
- Vol. 27 (6) , 965-978
Open AccessReal‐world use of second‐generation integrase strand transfer inhibitors ( INSTI ) as switch therapy in the prospective ANRS ‐ CO3 ‐ AquiVIH ‐ NA cohort
Objectives: To characterize real‐world treatment switching in France to bictegravir (BIC or B) or dolutegravir (DTG)‐based regimens with a focus on treatment persistence, effectiveness (HIV‐1 RNA ≤50 copies/ml) and particular attention to the prevalence and incidence of comorbidities. Methods: People living with HIV from the prospective ANRS‐CO3‐AquiVIH‐NA cohort, who switched from effective antiretroviral treatment (ART) to a BIC‐ or DTG‐based regimen between 2018 and 2021, were eligible for analysis. Results: A total of 2275 people living with HIV were included (52% receiving B/F/TAF, 8% DTG/3TC/ABC, 18% DTG/RPV, 22% DTG/3TC) with a median age of 53–56 years and a comorbidity prevalence of 71%–75% across treatment groups (chronic kidney disease (CKD) 15%–25%, diabetes mellitus 15%–19%, hypertension 57%–64%). Viral suppression rates at month 18 (LOCF, last observation carried forward) using a missing‐equals‐excluded (M = E) approach were 97% on B/F/TAF, 95% on DTG/3TC/ABC, 97% on DTG/RPV and 96% on DTG/3TC. Discontinuation rates were 16.5% for B/F/TAF, 37.5% for DTG/3TC/ABC, 16.7% for DTG/RPV and 17.3% for DTG/3TC, driven by adverse events in 5.6%, 12.5%, 5.6% and 6.1%, respectively. Comorbidity incidence rates/1000 person years in those free of the respective disease were 39 for hypertension, 22 for diabetes mellitus, 13 for cardiovascular events and 5 for CKD. Conclusions: In this real‐world cohort, treatment persistence 18 months after therapy switch was similar for B/F/TAF, DTG/RPV and DTG/3TC, but significantly lower for DTG/3TC/ABC. All regimens maintained high levels of viral suppression. Furthermore, the cohort illustrates the disease burden experienced by middle‐aged and elderly people living with HIV and highlights the importance of adapting ART to the specific needs of this population.
- Open Access
- 27 November 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (11) , e0298507
Feasibility and acceptability of a systematic offer of HIV rapid testing to Family Planning Centers visitors by non-physician professionals in France
Background: The Human Immunodeficiency Virus (HIV) epidemic remains active among women in Europe, with significant missed opportunities for HIV testing. Although HIV testing falls within the scope of Family Planning Centers (FPCs), it is often not offered. This pilot study assessed the feasibility and acceptability of systematically offering HIV rapid testing by non-physician professionals, independent of medical appointments, to visitors and accompanying persons in FCPs. Methods: In September 2020, three FPCs in the Paris region were selected for a 6-month pilot based on high local HIV diagnosis rates among women and the absence of an existing HIV rapid testing offer. A dedicated midwife coordinated a certified training course for non-physician professionals, including group discussions on obstacles and facilitators for offering HIV rapid testing, education on HIV and the use of HIV rapid tests, and the development of procedures, including a standardized HIV questionnaire, to systematically offer HIV rapid testing. We measured participation rates in the study and acceptability of the HIV rapid testing offer. We analyzed visitor characteristics, HIV risk factors and knowledge about HIV. Results: All non-physician professionals across the three FPCs were trained. HIV rapid testing was systematically offered to 261 incoming visitors and accompanying persons from September 2020 to March 2021: 93% completed the questionnaire, and 91% accepted the HIV rapid testing offer; 63% reported prior HIV risk behaviors. Visitors born in North Africa had the least knowledge about HIV. Twenty-two visitors declined the testing offer, citing recent HIV testing, no perceived lack of risk, feeling unprepared, or fear of the outcome. Conclusion: The results demonstrate the feasibility and strong acceptability of systematically offering HIV rapid testing by non-physician professionals in large urban FPCs. Extending this approach to include sexually transmitted infections (STIs) screening could be beneficial.
- 27 November 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (11) , e0298507
Open AccessFeasibility and acceptability of a systematic offer of HIV rapid testing to Family Planning Centers visitors by non-physician professionals in France
Background: The Human Immunodeficiency Virus (HIV) epidemic remains active among women in Europe, with significant missed opportunities for HIV testing. Although HIV testing falls within the scope of Family Planning Centers (FPCs), it is often not offered. This pilot study assessed the feasibility and acceptability of systematically offering HIV rapid testing by non-physician professionals, independent of medical appointments, to visitors and accompanying persons in FCPs. Methods: In September 2020, three FPCs in the Paris region were selected for a 6-month pilot based on high local HIV diagnosis rates among women and the absence of an existing HIV rapid testing offer. A dedicated midwife coordinated a certified training course for non-physician professionals, including group discussions on obstacles and facilitators for offering HIV rapid testing, education on HIV and the use of HIV rapid tests, and the development of procedures, including a standardized HIV questionnaire, to systematically offer HIV rapid testing. We measured participation rates in the study and acceptability of the HIV rapid testing offer. We analyzed visitor characteristics, HIV risk factors and knowledge about HIV. Results: All non-physician professionals across the three FPCs were trained. HIV rapid testing was systematically offered to 261 incoming visitors and accompanying persons from September 2020 to March 2021: 93% completed the questionnaire, and 91% accepted the HIV rapid testing offer; 63% reported prior HIV risk behaviors. Visitors born in North Africa had the least knowledge about HIV. Twenty-two visitors declined the testing offer, citing recent HIV testing, no perceived lack of risk, feeling unprepared, or fear of the outcome. Conclusion: The results demonstrate the feasibility and strong acceptability of systematically offering HIV rapid testing by non-physician professionals in large urban FPCs. Extending this approach to include sexually transmitted infections (STIs) screening could be beneficial.
- Open Access
- 22 October 2024
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 80 (1) , 95-101
Emergent resistance-associated mutations at first- or second-line HIV-1 virologic failure with second-generation InSTIs in two- and three-drug regimens: the Virostar-1 study
Second-generation integrase strand transfer inhibitors (InSTIs) have a high barrier to resistance and potent antiretroviral activity. They are recommended as first- or second-line (FL and SL) options in two- and three-drug regimens (2DR and 3DR) in international treatment guidelines. However, there are limited real-world data on emerging resistance at the time of virological failure (VF) with these regimens. The Virostar-1 study objective is to analyse the emergence of resistance-associated mutations (RAMs) over 3 years with DTG-based 2DRs and DTG- or bictegravir (BIC)-based 3DRs in people living with HIV (PLWH) experiencing a VF (FL or SL). Retrospective analysis of genotypic resistance detected at the time of a FL or SL VF with BIC/FTC/TAF, DTG/ABC/3TC, DTG/3TC and DTG/RPV between 2019 and 2022 was conducted from a French multicentre database. VF was defined as two consecutive HIV-1 plasma viral loads > 50 c/mL. Sanger assays were performed at VF within standard clinical care. Resistance mutations were reported using the ANRS algorithm. Selection biases prevent group comparisons. During the period, N = 5986 PLWH were followed either in FL or SL. The VF rate was overall low: BIC/FTC/TAF, 6.8%; DTG/ABC/3TC, 7.5%; DTG/3TC, 5.1%; and DTG/RPV, 2.1%. Some emergent InSTI or NRTI RAMs were detected with BIC/FTC/TAF 4%, DTG/ABC/3TC 8.5%, DTG/3TC 18% and 39% emergent NNRTI RAMs with DTG/RPV. However, a complete absence of dual resistance against NRTIs and InSTIs was observed. We detected rare emergent InSTI RAMs and few emergent NRTI RAMs in PLWH failing DTG- or BIC-based regimens in FL or SL. The observed rates of emergent RAMs at VF were 4% with BIC/FTC/TAF, 8.5% with DTG/ABC/3TC, 18% with DTG/3TC and 39% with DTG/RPV.
- 22 October 2024
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 80 (1) , 95-101
Open AccessEmergent resistance-associated mutations at first- or second-line HIV-1 virologic failure with second-generation InSTIs in two- and three-drug regimens: the Virostar-1 study
Second-generation integrase strand transfer inhibitors (InSTIs) have a high barrier to resistance and potent antiretroviral activity. They are recommended as first- or second-line (FL and SL) options in two- and three-drug regimens (2DR and 3DR) in international treatment guidelines. However, there are limited real-world data on emerging resistance at the time of virological failure (VF) with these regimens. The Virostar-1 study objective is to analyse the emergence of resistance-associated mutations (RAMs) over 3 years with DTG-based 2DRs and DTG- or bictegravir (BIC)-based 3DRs in people living with HIV (PLWH) experiencing a VF (FL or SL). Retrospective analysis of genotypic resistance detected at the time of a FL or SL VF with BIC/FTC/TAF, DTG/ABC/3TC, DTG/3TC and DTG/RPV between 2019 and 2022 was conducted from a French multicentre database. VF was defined as two consecutive HIV-1 plasma viral loads > 50 c/mL. Sanger assays were performed at VF within standard clinical care. Resistance mutations were reported using the ANRS algorithm. Selection biases prevent group comparisons. During the period, N = 5986 PLWH were followed either in FL or SL. The VF rate was overall low: BIC/FTC/TAF, 6.8%; DTG/ABC/3TC, 7.5%; DTG/3TC, 5.1%; and DTG/RPV, 2.1%. Some emergent InSTI or NRTI RAMs were detected with BIC/FTC/TAF 4%, DTG/ABC/3TC 8.5%, DTG/3TC 18% and 39% emergent NNRTI RAMs with DTG/RPV. However, a complete absence of dual resistance against NRTIs and InSTIs was observed. We detected rare emergent InSTI RAMs and few emergent NRTI RAMs in PLWH failing DTG- or BIC-based regimens in FL or SL. The observed rates of emergent RAMs at VF were 4% with BIC/FTC/TAF, 8.5% with DTG/ABC/3TC, 18% with DTG/3TC and 39% with DTG/RPV.
- Open Access
- 23 January 2024
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 79 (3) , 578-588
Use of genotypic HIV DNA testing: a DELPHI-type consensus
As many disparities in the clinical use of HIV DNA sequencing are observed, a DELPHI-type consensus was initiated in France to homogenize use, techniques and interpretation of results. Based on a literature review and clinical experience, a steering committee (SC) of eight virologists and one infectious disease specialist formulated statements. Statements were submitted to an independent and anonymous electronic vote of virologists and HIV clinicians in France, between October 2022 and December 2022. The SC developed 20 statements grouped into six categories: clinical situations for the use of HIV DNA genotyping; techniques for performing HIV DNA genotyping; consideration of apolipoprotein B mRNA editing enzyme (APOBEC) mutations; genotyping results reporting; recycling of antiretrovirals; and availability of HIV DNA genotyping tests and delays. Twenty-one virologists and 47 clinicians participated in two voting rounds and 18/20 (90%) assertions reached a ‘strong’ consensus. For example, that prior genotyping on HIV DNA is useful for clinical decision-making when considering switching to some long-acting regimens or to reduce the number of antiretroviral agents in virologically suppressed patients for whom RNA data are unavailable/not exploitable/not sufficiently informative. Two statements achieved no consensus: reporting any detected viral minority population for discussion in multidisciplinary meetings (virologists), and possible risk of virological failure when using a second-generation InSTI plus lamivudine or emtricitabine regimen in patients with undetectable viral load within ≥1 year and in the presence of a documented M184V mutation within the last 5 years (clinicians). This DELPHI-type consensus will facilitate the strengthening and harmonization of good practice when performing HIV DNA sequencing.
- 23 January 2024
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 79 (3) , 578-588
Open AccessUse of genotypic HIV DNA testing: a DELPHI-type consensus
As many disparities in the clinical use of HIV DNA sequencing are observed, a DELPHI-type consensus was initiated in France to homogenize use, techniques and interpretation of results. Based on a literature review and clinical experience, a steering committee (SC) of eight virologists and one infectious disease specialist formulated statements. Statements were submitted to an independent and anonymous electronic vote of virologists and HIV clinicians in France, between October 2022 and December 2022. The SC developed 20 statements grouped into six categories: clinical situations for the use of HIV DNA genotyping; techniques for performing HIV DNA genotyping; consideration of apolipoprotein B mRNA editing enzyme (APOBEC) mutations; genotyping results reporting; recycling of antiretrovirals; and availability of HIV DNA genotyping tests and delays. Twenty-one virologists and 47 clinicians participated in two voting rounds and 18/20 (90%) assertions reached a ‘strong’ consensus. For example, that prior genotyping on HIV DNA is useful for clinical decision-making when considering switching to some long-acting regimens or to reduce the number of antiretroviral agents in virologically suppressed patients for whom RNA data are unavailable/not exploitable/not sufficiently informative. Two statements achieved no consensus: reporting any detected viral minority population for discussion in multidisciplinary meetings (virologists), and possible risk of virological failure when using a second-generation InSTI plus lamivudine or emtricitabine regimen in patients with undetectable viral load within ≥1 year and in the presence of a documented M184V mutation within the last 5 years (clinicians). This DELPHI-type consensus will facilitate the strengthening and harmonization of good practice when performing HIV DNA sequencing.
- Open Access
- 8 November 2023
- Published by Wiley in Journal of Sleep Research
- Vol. 33 (3) , e14070
The screening and management of sleep disturbances in people living with HIV: Delphi consensus
Summary: Sleep disturbances in people living with HIV (PLHIV) are frequent but their management remains insufficient. In the absence of specific recommendations, a DELPHI consensus research project was conducted in France to establish best practice. A multidisciplinary Steering Committee (STC) undertook a literature review and used it with clinical expertise to create statements that were voted on. Two profiles of healthcare professionals with significant experience in monitoring PLHIV were selected for the voting: physicians and nurses/psychologists. Votes were collected electronically, independently, and anonymously. The STC created 27 statements covering six areas: Screening of sleep disturbances, Investigation, First‐line management, Referral to a specialist, Antiretroviral treatment (ARV), and Prevention. Two rounds of votes included 42 physicians and 32 nurses/psychologists. Consensus was reached for 24 out of 27 statements (89%) including: to assess quantity and quality of sleep among PLHIV at least annually, ideally using a common methodology within the medical department; to consider the temporary addition of a hypnotic treatment in cases of acute insomnia not improved by the rules of sleep hygiene, with full awareness of potential drug–drug interactions and risk of dependence; to correct ferritinaemia if <100 ng/mL before referral to a specialist when restless legs syndrome is suspected; to consider changing the time of ARV administration or an ARV switch within the same class when sleep disturbances are caused by an ARV. This DELPHI Consensus provides best practice for screening and managing sleep disturbances in PLHIV and optimising their quality of life.
- 8 November 2023
- Published by Wiley in Journal of Sleep Research
- Vol. 33 (3) , e14070
Open AccessThe screening and management of sleep disturbances in people living with HIV: Delphi consensus
Summary: Sleep disturbances in people living with HIV (PLHIV) are frequent but their management remains insufficient. In the absence of specific recommendations, a DELPHI consensus research project was conducted in France to establish best practice. A multidisciplinary Steering Committee (STC) undertook a literature review and used it with clinical expertise to create statements that were voted on. Two profiles of healthcare professionals with significant experience in monitoring PLHIV were selected for the voting: physicians and nurses/psychologists. Votes were collected electronically, independently, and anonymously. The STC created 27 statements covering six areas: Screening of sleep disturbances, Investigation, First‐line management, Referral to a specialist, Antiretroviral treatment (ARV), and Prevention. Two rounds of votes included 42 physicians and 32 nurses/psychologists. Consensus was reached for 24 out of 27 statements (89%) including: to assess quantity and quality of sleep among PLHIV at least annually, ideally using a common methodology within the medical department; to consider the temporary addition of a hypnotic treatment in cases of acute insomnia not improved by the rules of sleep hygiene, with full awareness of potential drug–drug interactions and risk of dependence; to correct ferritinaemia if <100 ng/mL before referral to a specialist when restless legs syndrome is suspected; to consider changing the time of ARV administration or an ARV switch within the same class when sleep disturbances are caused by an ARV. This DELPHI Consensus provides best practice for screening and managing sleep disturbances in PLHIV and optimising their quality of life.